NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Operating Leases came in at $834000.0 in Q2 2026, down 10.71% quarter-over-quarter from $934000.0 in Q1 2026.

Analysis

NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Operating Leases for 2 consecutive years, with $834000.0 the latest figure, recorded in Q2 2026.

On a quarterly basis, Operating Leases changed N/A year-over-year to $834000.0 in Q2 2026; TTM through Jun 2026 was $834000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $631000.0, changed N/A from the prior year.
Operating Leases was $834000.0 for Q2 2026 at NRX Pharmaceuticals, down from $934000.0 in the prior quarter.
Over five years, Operating Leases peaked at $934000.0 in Q1 2026 and troughed at $143000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	NRX Pharmaceuticals	127.63 Mn	100.93 Mn	426,000.00

Historic Data

Download Data